The aging male : the official journal of the International Society for the Study of the Aging Male · 2025
Effectiveness and safety of degarelix compared to GnRH agonists for prostate cancer: a systematic review and meta-analysis.
СтатьяСистематический обзорМетаанализСравнительное исследованиеНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Chai Yumeng, Yao Zhuoyue, Zhou Zhongbao, Zhang Yong
Аннотация
BACKGROUND AND OBJECTIVE: This meta-analysis compared the efficacy and safety of degarelix and GnRH agonists in prostate cancer treatment.
METHODS: A comprehensive literature search was carried out using PubMed, Web of Science, Cochrane Library, and Scopus. RevMan 5.3 software was applied to conduct the meta-analysis.
RESULTS: Degarelix resulted in a higher frequency of adverse events compared to GnRH agonists (59.7% vs 48.4%; RR: 1.07, 95%CI: 1.02-1.13, p < 0.001). However, these events did not translate into a higher rate of severe complications (10.8% vs 11.8%; RR: 0.89, 95%CI: 0.66-1.19, p = 0.43), treatment discontinuation (5.5% vs 5.5%; RR:1.00, 95%CI: 0.67-1.50, p = 0.99) or death (2.5% vs 3.9%; RR: 0.64, 95%CI: 0.34-1.19, p = 0.16). Degarelix triggered higher incidence of injection site reaction (45.3%vs 4.4%; RR: 19.17, 95%CI: 5.51-66.74, p < 0.00001), but contributed to lower rates of cardiovascular events (6.1% vs 7.8%; RR: 0.7, 95%CI: 0.51-0.96, p = 0.03), musculoskeletal events (12.7% vs 15.2%; RR: 0.79, 95%CI: 0.65-0.95, p = 0.01) and urinary adverse effects (AEs) (6.4% vs 14.1%; RR: 0.46, 95%CI: 0.33-0.63, p < 0.00001). Degarelix provided better relief of IPSS (MD -1.85, 95%CI: -2.97- -0.72, P = 0.001) and was linked to reduced prostate volume (MD -1.4, 95%CI: -4.83-2.02, P = 0.42). There was no significant difference in PSA progression at 12 months (13.3% vs 14%; RR: 0.88, 95%CI: 0.73-1.06, p = 0.17). However, degarelix achieved significantly higher castration rates at day 3 (96.5% vs 0%; RR: 356.05, 95%CI: 87.57-1447.68, p < 0.00001) and more sustained testosterone suppression at 12 months (96.1% vs 74.3%; RR: 1.3, 95%CI: 1.02-1.66, p = 0.03).
CONCLUSIONS AND CLINICAL IMPLICATIONS: While degarelix is associated with higher overall AE rates, it provides significant benefits in terms of cardiovascular and musculoskeletal safety, rapid testosterone suppression, and lower urinary AEs.
METHODS: A comprehensive literature search was carried out using PubMed, Web of Science, Cochrane Library, and Scopus. RevMan 5.3 software was applied to conduct the meta-analysis.
RESULTS: Degarelix resulted in a higher frequency of adverse events compared to GnRH agonists (59.7% vs 48.4%; RR: 1.07, 95%CI: 1.02-1.13, p < 0.001). However, these events did not translate into a higher rate of severe complications (10.8% vs 11.8%; RR: 0.89, 95%CI: 0.66-1.19, p = 0.43), treatment discontinuation (5.5% vs 5.5%; RR:1.00, 95%CI: 0.67-1.50, p = 0.99) or death (2.5% vs 3.9%; RR: 0.64, 95%CI: 0.34-1.19, p = 0.16). Degarelix triggered higher incidence of injection site reaction (45.3%vs 4.4%; RR: 19.17, 95%CI: 5.51-66.74, p < 0.00001), but contributed to lower rates of cardiovascular events (6.1% vs 7.8%; RR: 0.7, 95%CI: 0.51-0.96, p = 0.03), musculoskeletal events (12.7% vs 15.2%; RR: 0.79, 95%CI: 0.65-0.95, p = 0.01) and urinary adverse effects (AEs) (6.4% vs 14.1%; RR: 0.46, 95%CI: 0.33-0.63, p < 0.00001). Degarelix provided better relief of IPSS (MD -1.85, 95%CI: -2.97- -0.72, P = 0.001) and was linked to reduced prostate volume (MD -1.4, 95%CI: -4.83-2.02, P = 0.42). There was no significant difference in PSA progression at 12 months (13.3% vs 14%; RR: 0.88, 95%CI: 0.73-1.06, p = 0.17). However, degarelix achieved significantly higher castration rates at day 3 (96.5% vs 0%; RR: 356.05, 95%CI: 87.57-1447.68, p < 0.00001) and more sustained testosterone suppression at 12 months (96.1% vs 74.3%; RR: 1.3, 95%CI: 1.02-1.66, p = 0.03).
CONCLUSIONS AND CLINICAL IMPLICATIONS: While degarelix is associated with higher overall AE rates, it provides significant benefits in terms of cardiovascular and musculoskeletal safety, rapid testosterone suppression, and lower urinary AEs.